Company: DMAC
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001437749-25-009696
Chunk: 58

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 58
---
     |               |  22,500 |     |          | (US$) 2.45   |     | 05/31/2032 |     |              |     |            |
|                        |     |                  | 25,125 |     |               |  41,875 |     |          | (US$) 2.73   |     | 05/31/2033 |     |              |     |            |
|                        |     |                  |      — |     |               | 130,000 |     |          | (US$) 2.90   |     | 05/31/2034 |     |              |     |            |

| (1) | The stock options that remained unvested as of December 31, 2024 generally vest monthly or quarterly and may be accelerated under certain circumstances, including if the recipient’s employment or service relationship with our Company is involuntarily terminated. |

| (2) | All stock options have a 10-year term but may terminate earlier if the recipient’s employment or service relationship with our Company terminates. |

| (3) | All DSU awards are settled after the holder’s employment or service relationship with our Company terminates. |

| (4) | The market value of DSU awards that have not been settled as of December 31, 2024 is based on the closing sale price of our common shares as reported by The Nasdaq Capital Market on December 31, 2024 ($5.43). |

Pay Versus Performance Disclosure

As required by Section 953(a) of the Dodd-Frank Act and Item 402(v) of SEC Regulation S-K, we are providing the following information about the relationship between “compensation actually paid” to our named executive officers, within the meaning of such rules, and certain financial performance measures of our Company.

The table below provides information regarding compensation actually paid to our CEO who is our principal executive officer (PEO), and the average compensation actually paid to our other non-PEO named executive officers, during each of the past three fiscal years, as well as total shareholder return and net income (loss) for each of the past three fiscal years.

|      | Year |   |      Summary 
 Compensation 
  Table Total 
   for PEO(1) |     |   |  Compensation 
 Actually Paid 
  to PEO(2)(3) |     |   |      Average 
      Summary 
 Compensation